Nucletron separates from Delft; looks towards half-billion-dollar mark
This article was originally published in Clinica
Executive Summary
Radiation oncology specialist Nucletron has targeted a three-fold increase in revenue within the next five years, following its recent successful spin-off from parent company Delft Instruments. Over the last few years, Delft has been selling many of its non-core subsidiaries in an attempt to focus on the oil and gas industry. This led to Nucletron proposing a management buy-out. The separation, which took effect from July 1, provides Nucletron with its own share capital and allows the company to progress towards a proposed employee-wide shareholding. Nucletron recorded sales of E120m ($165m) in 2006, but since becoming an independent player situated in the top four radiotherapy companies worldwide, the Dutch firm believes it can close the gap on the top three radiotherapy oncology giants Siemens, Elekta and Varian Medical Systems.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.